ClinicalTrials.gg
CompletedNCT06780410Updated Nov 13, 2026

A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

A Phase 3 interventional study of Bempedoic Acid Tablet and Placebo in Primary Hyperlipidemia, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Hyperlipidemias with a site in China — 29 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
28th of 78
245 · median 155
Started
2024
with 10 others
Phase 3
20 of 94
4 open now
Registered
65th of 94
by date

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 28th largest by enrollment of the 78 interventional ones that give a count, is one of 11 that started in 2024, is one of 20 in phase 3, and was the 65th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

29 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This trial is a phase III study to evaluate the efficacy , tolerability, and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.

03

Conditions studied

  • Primary Hyperlipidemia

Browse trials for

Keywords

  • Bempedoic Acid
  • Hyperlipidemia
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. 18 years and older, male or female.
  • 2. 18 kg/m2 ≤ (BMI) ≤35 kg/m2.
  • 3. Participants must agree to use reliable from the screening day until 30 days after the last dose, and must not donate sperm or eggs for assisted reproduction purposes.
  • 4. Fully understand the purpose and requirements of the study, voluntarily participate in the clinical trial, and sign a written form, capable of completing the entire study process.

Exclusion criteria

Exclusion Criteria:

  • 1. Known allergy to any component of the drug or its , or a history of allergic diseases (e.g., asthma, urticaria, eczema) or allergic constitution.
  • 2. Fasting triglycerides (TG) ≥ 5.64 mmol/L (≥ 500 mg/dL) at screening.
  • 3. History of malignant tumors prior to screening.
  • 4. History of drug, alcohol, amphetamines, or other drug abuse.
  • 5. Participation in other clinical studies and use of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of the drugs (whichever is longer).
  • 6. Pregnant or breastfeeding females, or those with a positive human chorionic gonadotropin (HCG) pregnancy test.
  • 7. Any other factors that the investigator believes makes the participant unsuitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Bempedoic acid

    Once daily

  • Placebo comparator
    Placebo

    Once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in LDL-C levels at Week 12

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage change from baseline in total cholesterol (TC) levels at Week 12

    Time frame: Baseline, Week 12

  2. Adverse events (AEs) and serious adverse events (SAEs) during the study

    Time frame: Baseline, Week 13

07

Study locations

1 site
  • Site 01
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2025, 7 months.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Oct 2025 → Aug 2025 and completion Oct 2025 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Dec 20, 2024
Primary completionActual
Aug 5, 2025was Oct 2025
CompletionActual
Aug 11, 2025was Oct 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Oct 2025→Aug 5, 2025 (actual)
Nov 13, 2026
Study completion
Oct 2025→Aug 11, 2025 (actual)
Nov 13, 2026
Enrollment
240 (estimated)→245 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Oct 2025→Aug 5, 2025 (now actual)
    Study completion Oct 2025→Aug 11, 2025 (now actual)
    Enrollment 240 (estimated)→245 (actual)
    + 6 other changes: identifiers, oversight details, arm descriptions, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06780410
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Dec 20, 2024
Primary completion
Aug 5, 2025
Completion
Aug 11, 2025
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion